(-0.08%) 5 304.25 points
(-0.09%) 40 140 points
(-0.05%) 18 465 points
(-0.07%) $83.11
(-0.62%) $1.752
(0.73%) $2 254.80
(0.74%) $25.10
(0.21%) $923.00
(0.16%) $0.928
(0.19%) $10.86
(0.02%) $0.792
(-0.38%) $92.23
Live Chart Being Loaded With Signals
Acticor Biotech SAS operates as a clinical stage biotechnology company that develops drugs for the treatment of acute phase of thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets a specific platelet glycoprotein...
Stats | |
---|---|
Today's Volume | 4 463.00 |
Average Volume | 21 500.00 |
Market Cap | 50.57M |
EPS | €0 ( 2023-10-26 ) |
Last Dividend | €0 ( N/A ) |
Next Dividend | €0 ( N/A ) |
P/E | -1.920 |
ATR14 | €0.0160 (0.50%) |
Groupe Actiplay SA Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Groupe Actiplay SA Financials
Annual | 2022 |
Revenue: | €0 |
Gross Profit: | €-86 000.00 (0.00 %) |
EPS: | €-1.580 |
Q2 | 2023 |
Revenue: | €0 |
Gross Profit: | €-7 000.00 (0.00 %) |
EPS: | €-0.870 |
Q1 | 2023 |
Revenue: | €0 |
Gross Profit: | €0 (0.00 %) |
EPS: | €-0.440 |
Q4 | 2022 |
Revenue: | €0 |
Gross Profit: | €-50 000.00 (0.00 %) |
EPS: | €-0.810 |
Financial Reports:
No articles found.
Groupe Actiplay SA
Acticor Biotech SAS operates as a clinical stage biotechnology company that develops drugs for the treatment of acute phase of thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets a specific platelet glycoprotein. It is also involved in two clinical programs in Phase II/III registration for the treatment of ischemic stroke; and two other Phase II trials addressing major cardiovascular emergencies with clinical results expected in ischemic stroke and Covid-19 respiratory distress syndrome. The company was incorporated in 2013 and is headquartered in Paris, France.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators